Clinical Trials of Intensive Glucose Control on Cardiovascular Disease Risk
TRIAL, YEARS (REF.) | INTERVENTION | CONTROL | SAMPLE SIZE | AVERAGE FOLLOW-UP (YEARS) | CARDIOVASCULAR ENDPOINT | RELATIVE RISK REDUCTION | P- VALUE |
|---|---|---|---|---|---|---|---|
| DCCT/EDIC, 1983–2013 (159,165) | Intensive insulin therapy | Conventional insulin therapy | 1,441 | 6.5 / extended follow-up for additional 19.5 years | Total CVD | 41% / 30% | NS / 0.02 |
| UKPDS, 1977–2007 (160,161,166) | Intensive sulfonylurea- insulin, metformin | Conventional with diet | 4,209 | 10 / extended follow-up for additional 8.5 years | MI | 16% / 15% | 0.052 / 0.01 |
| ADVANCE, 2001–2008 (162) | Gliclazide plus other oral drugs to achieve A1c <6.5% | Standard drugs | 11,140 | 5 | Nonfatal MI, nonfatal stroke, or CVD death | 6% | 0.32 |
| ACCORD, 2001–2007 (163) | Intensive therapy targeting A1c <6.0% | Standard therapy for A1c 7.0%–7.9% | 10,251 | 3.5 | Nonfatal MI, nonfatal stroke, or CVD death | 10% | 0.16 |
| VADT, 2000–2008 (164) | Intensive control | Standard drugs | 1,791 | 5.6 | Total CVD events | 12% | 0.14 |
Conversion formulas for A1c values are provided in the Conversions section. A1c, glycosylated hemoglobin; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; CVD, cardiovascular disease; DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study; MI, myocardial infarction; NS, non-significant; UKPDS, United Kingdom Prospective Diabetes Study; VADT, Veterans Affairs Diabetes Trial.
SOURCE: References are listed within the table.
From: Heart Disease and Diabetes
Diabetes in America is in the public domain of the United States. You may use the work without restriction in the United States.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.